查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733192

全球格雷夫兹病市场规模（按诊断、治疗、地区和预测）

Global Graves Disease Market Size By Diagnosis (Ultrasound, Imaging Tests, Radioactive Iodine Uptake), By Treatment (Anti- Thyroid Medication, Radioactive Iodine Therapy, Surgery), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

格雷夫兹病的市场规模与预测

2024 年格雷夫兹病市场规模价值 3.6266 亿美元，预计到 2032 年将达到 5.1877 亿美元，2026 年至 2032 年的复合年增长率为 4.82%。

推动全球格雷夫兹病市场的因素

格雷夫兹病市场的市场驱动因素可能受到多种因素的影响。这些包括：

  • 格雷夫斯病患病率不断上升：主要因素之一是格雷夫斯病患病率不断上升，这是一种导致甲状腺亢进的自体免疫疾病。随着确诊病例增多，对有效治疗方法的需求也随之增加
  • 改进的治疗方法：内分泌学的治疗方法和发展正在为格雷夫兹病带来新的、更好的治疗方法。药物治疗的创新，包括生技药品和小分子药物，正在改善患者的治疗效果和治疗反应。
  • 更好的诊断：诊断技术的进步，例如自体抗体检测和甲状腺功能检测，使得格雷夫兹病的早期和准确诊断成为可能。早期诊断对于有效的管理和治疗至关重要。
  • 提升知识和教育程度：大众和医学界对格雷夫兹病的了解越多，诊断越多，治疗越及时。病患权益团体和教育宣传活动是提高人们对病情和可用治疗方法的认识的重要工具。
  • 人口老化：随着世界人口老化，格雷夫兹病和其他自体免疫疾病变得越来越普遍。自体免疫疾病在老年人中很常见，治疗需求日益增加
  • 医疗保健机会的增加：医疗保健服务的改善，特别是在开发中国家，导致格雷夫兹病的诊断和治疗增加。这一趋势是由政府努力改善医疗基础设施和医疗改革所推动的。
  • 个人化医疗需求日益增加：个人化医疗越来越受欢迎。这涉及根据患者的基因、环境和生活方式特征做出治疗决定。此方法对治疗格雷夫兹病等自体免疫疾病非常有效。
  • 未治疗疾病的经济负担：未治疗或管理不善的格雷夫斯病（包括甲状腺眼疾和心血管问题等併发症）的经济负担是巨大的，需要有效的治疗方法来避免这些昂贵的併发症。
  • 为了改善格雷夫兹病的治疗现状并鼓励开发新的治疗方法，增加公共和私营部门实体以及製药公司的研发资金将会有所帮助。
  • 技术创新：标靶治疗和缓释性製剂等药物传递方法的发展可以为格雷夫兹病患者提供更方便、有效的治疗选择。

限制全球格雷夫兹病市场的因素

有几个因素可能会对格雷夫兹病市场造成限製或挑战。这些包括：

  • 昂贵的治疗：药物治疗、放射性碘治疗和手术都是格雷夫兹病昂贵的治疗方法的一部分。高昂的费用可能会使患者无法接受这些治疗，尤其是在医疗保险和资金匮乏的地区。
  • 格雷夫兹病的治疗方法包括放射性碘、抗甲状腺药物和切除术，可能会产生严重的副作用和安全问题。这些副作用限制了它们的使用，并可能导致患者停止服药或不遵守治疗计划。
  • 知识和诊断有限：公众和一些卫生专业人员通常对格雷夫斯病知之甚少或不甚了解。诊断和治疗的延迟会影响患者的治疗结果和市场需求。
  • 严格的监管标准：治疗格雷夫兹病的新药必须通过严格的监管标准，这使得其生产成本高且耗时。监管障碍可能会延迟新疗法的推出并增加相关成本。
  • 竞争性替代疗法：放射性碘疗法、抗甲状腺药物和手术是治疗方法的一些有效方法。为了被市场接受，新治疗方法必须被证明比现有治疗方法更有益，这可能很困难。
  • 治疗反应各异：格雷夫兹病患者对不同治疗方法的反应不同，因此很难知道哪种治疗方法对每位患者最有效。这种不可预测性会使治疗计划更加困难，并降低治疗的整体成功率。
  • 最低限度的研究和开发：与其他慢性疾病相比，格雷夫兹病患者的数量非常少，因此对新治疗方法的研究和开发可能会受到限制。这可能会阻碍治疗方法的进步和商业化。
  • 经济限制：景气衰退和医疗保健系统预算限制可能会影响格雷夫兹病昂贵治疗方法的接受度。在景气衰退期间，公共和商业部门对新疗法的资金筹措可能会受到限制。
  • 保险和付款问题：对于较新、较昂贵的格雷夫兹病治疗，保险覆盖范围和付款有所不同。如果患者必须支付高额的自付费用，他们可能不会寻求最好的照护。
  • 患者依从性：长期使用药物加上格雷夫兹病的慢性性质可能会对患者的依从性带来问题。需要频繁监测以及可能出现的严重副作用可能会影响治疗方法的依从性。

目录

第一章 全球格雷夫兹病市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球格雷夫兹病市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球格雷夫兹病市场（以最终用户划分）

  • 概述
  • 医院
  • 专科诊所
  • 门诊手术中心
  • 居家医疗

6. 全球格雷夫兹病市场（按治疗）

  • 概述
  • 抗甲状腺药物
  • 放射性碘治疗
  • β受体阻断剂
  • 外科治疗
  • 辅助性治疗
  • 新的治疗方法

7. 全球格雷夫兹病市场（依分销管道）

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局
  • 专业药房

8. 全球格雷夫兹病市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东

第八章全球格雷夫兹病市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第九章 公司简介

  • Merck & Co., Inc.
  • Abbott Laboratories
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Allergan, plc
  • RLC LABS
  • Mylan NV
  • AbbVie, Inc.

第十章 附录

  • 相关调查
简介目录
Product Code: 33167

Graves Disease Market Size And Forecast

Graves Disease Market size was valued at USD 362.66 Million in 2024 and is projected to reach USD 518.77 Million by 2032, growing at a CAGR of 4.82% from 2026 to 2032.

Global Graves Disease Market Drivers

The market drivers for the Graves Disease Market can be influenced by various factors. These may include:

  • Growing Prevalence of Graves' Disease: One of the main causes is the rising prevalence of Graves' disease, an autoimmune condition that causes hyperthyroidism. The need for efficient therapies is increasing as more instances are diagnosed.
  • Improvements in Treatment Options: New and better treatments for Graves' disease have been developed as a result of ongoing endocrinology research and development. Drug therapy innovations, such as biologics and small molecule medications, improve patient outcomes and treatment efficacy.
  • Better Diagnostic Methods: The early and more accurate diagnosis of Graves' disease is made possible by technological advancements in diagnostics, such as less intrusive and more accurate tests for autoantibodies and thyroid function. For management and treatment to be effective, early diagnosis is essential.
  • Enhanced Knowledge and Education: A greater public and medical community understanding of Graves' illness results in a greater number of diagnoses and prompt medical management. Patient advocacy groups and educational campaigns are important tools for raising awareness of the symptoms and available treatments.
  • Ageing Population: Graves' disease and other autoimmune disorders are becoming more common as a result of the world's ageing population. Autoimmune disorders are more common in older persons, which increases the need for medical treatments.
  • Increased Access to Healthcare: More cases of Graves' illness are diagnosed and treated as a result of improved access to healthcare services, especially in developing nations. This tendency is facilitated by government initiatives and healthcare reforms that attempt to improve the infrastructure of healthcare.
  • Growing Need for Personalised Medicine: Personalised medicine is becoming more and more popular. It bases treatment decisions on a patient's genetic, environmental, and lifestyle characteristics. This method is very useful for treating autoimmune conditions such as Graves' disease.
  • Economic Burden of Untreated illness: The need for efficient treatments that can avert these expensive complications is driven by the significant economic burden that results from untreated or inadequately managed Graves' illness, including complications like thyroid eye disease and cardiovascular problems.
  • Increased financing for research and development from public and private institutions as well as pharmaceutical corporations helps to improve the current landscape of treatments for Graves' disease and encourage the development of new treatment modalities.
  • Technological Innovations: Patients with Graves' disease benefit from more convenient and effective treatment options thanks to technological developments in drug delivery methods, including as targeted therapy and sustained-release formulations.

Global Graves Disease Market Restraints

Several factors can act as restraints or challenges for the Graves Disease Market. These may include:

  • Expensive Treatment: Medication, radioactive iodine therapy, and surgery are all part of the costly treatment for Graves' illness. Exorbitant expenses may prevent patients from receiving these therapies, particularly in areas with little insurance or financing for healthcare.
  • Treatments for Graves' illness, including radioactive iodine, antithyroid drugs, and thyroidectomy, can have serious adverse effects and raise safety issues. These side effects may restrict their use and cause patients to stop taking their medication or not comply with their treatment plan.
  • Restricted Knowledge and Diagnosis: The general public, as well as some healthcare professionals, frequently have a poor knowledge and comprehension of Graves' illness. Delayed diagnosis and treatment might have an impact on patient outcomes and market demand.
  • Strict Regulatory criteria: New medicines for Graves' disease must pass strict regulatory criteria, which can be expensive and time-consuming to produce. Regulatory obstacles have the potential to postpone the launch of novel treatments and raise their associated expenses.
  • Competition from Alternative Therapies: Radioactive iodine therapy, antithyroid medications, and surgery are some of the proven treatments for Graves' illness. To be accepted by the market, new treatments must shown to be significantly more beneficial than these current options, which might be difficult.
  • Variability in Treatment Response: Individuals with Graves' illness may react differently to various therapies, making it challenging to determine which course of action will work best for each patient. This unpredictability can make treatment plans more difficult to follow and lower the overall success rates of therapy.
  • Minimal Research and Development: Compared to other chronic diseases, Graves' disease patients are very small, hence research and development for novel treatments may be scarce. This may impede the rate of advancement and the launch of novel treatments.
  • Economic Constraints: The adoption of expensive therapies for Graves' disease may be impacted by downturns in the economy and budgetary restrictions in healthcare systems. During recessions, financing for novel treatments from the public and commercial sectors may be constrained.
  • Problems with Insurance and payment: When it comes to newer and more costly therapies, insurance coverage and payment for Graves' disease treatments can be uneven. Significant out-of-pocket expenses for patients may discourage them from obtaining the best care possible.
  • Patient Compliance: Long-term pharmaceutical use combined with the chronic nature of Graves' illness may cause problems with patient compliance. Adherence to treatment methods may be impacted by the necessity for frequent monitoring and the possibility of serious adverse effects.

Global Graves Disease Market: Segmentation Analysis

The Global Graves Disease Market is Segmented on the basis of Treatment Type, End-User, Distribution Channel, and Geography.

Graves Disease Market, By Treatment Type

  • Anti-Thyroid Medications: Drugs used to reduce the production of thyroid hormones. Common medications include methimazole (Tapazole) and propylthiouracil (PTU).
  • Beta-Blockers: Medications that help manage symptoms such as rapid heart rate, tremors, and anxiety. Examples include propranolol and atenolol.
  • Radioactive Iodine Therapy: A treatment that involves ingesting radioactive iodine to destroy overactive thyroid cells, reducing thyroid hormone production.
  • Surgery (Thyroidectomy): A surgical procedure to remove all or part of the thyroid gland, typically used when other treatments are not suitable or effective.
  • Adjunctive Therapies: Supportive treatments including corticosteroids to manage inflammation and immune responses associated with Graves' disease.
  • Emerging Treatments: New therapies under development, including biologics and targeted therapies aimed at the underlying autoimmune aspects of the disease.

Graves Disease Market, By End-User

  • Hospitals: Facilities where comprehensive treatment options including surgery and radioactive iodine therapy are provided.
  • Specialty Clinics: Clinics specializing in endocrinology and thyroid disorders offering specialized care and treatment plans for Graves' disease.
  • Ambulatory Surgical Centers: Outpatient facilities where surgical treatments such as thyroidectomy can be performed.
  • Homecare Settings: For patients managing their condition with medications and regular monitoring at home.

Graves Disease Market, By Distribution Channel

  • Hospital Pharmacies: Pharmacies located within hospitals that dispense medications and provide treatment-related supplies.
  • Retail Pharmacies: Community pharmacies where patients can obtain prescribed medications.
  • Online Pharmacies: E-commerce platforms providing an accessible way for patients to order and receive their medications.
  • Specialty Pharmacies: Pharmacies that focus on complex and chronic conditions, offering personalized services and specialized medications.

Graves Disease Market, By Geography

  • North America: A major market driven by a high prevalence of autoimmune diseases, advanced healthcare infrastructure, and significant R&D activities.
  • Europe: A significant market with growing awareness and diagnosis of thyroid disorders, supported by robust healthcare systems.
  • Asia-Pacific: A rapidly growing market due to increasing healthcare access, rising prevalence of thyroid disorders, and improving healthcare infrastructure.
  • Latin America: An emerging market with increasing healthcare investments and growing awareness about thyroid health.
  • Middle East and Africa: A developing market with improving healthcare facilities and increasing efforts to diagnose and treat thyroid disorders.

Key Players

The "Global Graves Disease Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Merck & Co., Inc., Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline plc, Allergan, plc, RLC LABS, Mylan N.V., AbbVie, Inc., F .Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Jubilant Pharma Holdings Inc., Apitope International NV, Quintiles Inc., Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL GRAVES DISEASE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL GRAVES DISEASE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL GRAVES DISEASE MARKET, BY End-User

  • 5.1 Overview
  • 5.2 Hospitals
  • 5.3 Specialty Clinics
  • 5.4 Ambulatory Surgical Centers
  • 5.5 Homecare Settings

6 GLOBAL GRAVES DISEASE MARKET, BY TREATMENT

  • 6.1 Overview
  • 6.2 Anti-Thyroid Medication
  • 6.3 Radioactive Iodine Therapy
  • 6.4 Beta-Blockers
  • 6.6 Surgery
  • 6.7 Adjunctive Therapies
  • 6.8 Emerging Treatments

7 GLOBAL GRAVES DISEASE MARKET, BY Distribution Channel

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.6 Specialty Pharmacies

8 GLOBAL GRAVES DISEASE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East

8 GLOBAL GRAVES DISEASE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Merck & Co., Inc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Abbott Laboratories
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Pfizer, Inc.
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 GlaxoSmithKline plc
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Allergan, plc
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 RLC LABS
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Mylan N.V.
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 AbbVie, Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments

10 Appendix

  • 10.1 Related Research"